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Abstract
Background Inflammatory bowel disease (IBD) is increas-
ingly common among non-Caucasian populations, but
interracial differences in disease characteristics and man-
agement are not well-characterized.
Aims We tested the hypothesis that disease characteristics
and management vary by race among IBD patients in an
ethnically diverse healthcare system.
Methods A retrospective study of the safety net healthcare
system of San Francisco, CA, from 1996 to 2009 was
undertaken. Patient records with International Classification
of Diseases, 9th Revision (ICD9) codes 555.xx, 556.xx, and
558.xx were reviewed. Adult patients with confirmed IBD
diagnoses were included. Interracial variations in disease
characteristics and management were assessed broadly;
focused between-race comparisons identified specific
differences.
Results The 228 subjects included 77 (33.4%) with Cro-
hn’s disease (CD), 150 (65.8%) with ulcerative colitis, and 1
(0.4%) with IBD, type unclassified. The race distribution
included 105 (46.1%) white, 34 (14.9%) black, 35 (15.4%)
Hispanic, and 51 (22.4%) Asian subjects. Asians and
Hispanics were diagnosed at older ages (41.0 and 37.1 years,
respectively) and had shorter disease durations (5.4 and
5.2 years, respectively) than whites (30.5 years at diagnosis
and 8.6 years duration, P \ 0.05) and blacks (31.7 years at
diagnosis and 12.1 years duration, P \ 0.05). CD was more
common among blacks (50% of subjects) than Asians
(25.5% of subjects, P = 0.015). The Montreal classification
of IBD was similar among races. Hispanics were less likely
than others to be treated with 5-aminosalicylates (5-ASA),
immunomodulators, and steroids. Medical and surgical
management was otherwise similar among races.
Conclusions Modest race-based differences in IBD
characteristics exist in this racially diverse healthcare
system, but the management of IBD is similar among race
groups.
Keywords Inflammatory bowel diseases 
Colitis, ulcerative  Crohn’s disease  Race 
Ethnic groups  Health status disparities
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) were
previously considered to be diseases of Caucasian patients,
but studies have documented the increasing burden of
inflammatory bowel disease (IBD) among non-white pop-
ulations outside the United States [1–8]. Increasing hospi-
talization rates among minorities with IBD in the United
States may suggest similar trends, but nationwide epide-
miologic data (such as incidence and prevalence) are not
available [9].
Certain disease characteristics, such as penetrating dis-
ease (among patients with CD) [10] and extensive colitis
(among patients with UC) [11], are associated with poorer
disease outcomes, but studies comparing these important
disease characteristics among racially diverse populations
are extremely limited. Interracial differences in medical
and surgical therapy are also poorly characterized; most of
the few existing studies suffer from referral and/or selec-
tion bias, and potential healthcare disparities may, there-
fore, go undetected. To date, only one study evaluated IBD
in more than two race groups among patients from the
same geographic region [12]. One other study compared
IBD among three ethnic groups, but minority subjects were
recruited from different centers compared to the white
subjects [13].
The safety net healthcare system of San Francisco, CA,
serves approximately one-fifth of the city’s population and
is racially diverse [14, 15], providing an ideal setting in
which to address the above knowledge gaps. In an effort to
better understand associations between race and IBD, we
identified IBD patients seen in the gastroenterology clinic
serving this entire healthcare system from 1996 through
2009. We compared patients from four race groups to test
the hypothesis that disease characteristics and manage-
ment would differ among race groups. Based on prior
studies documenting healthcare disparities among minority
patients with other chronic diseases [16, 17], we hypothe-
sized that minority patients would have more severe dis-
ease manifestations and be less likely to receive medical
and surgical therapy compared with white patients.
Methods
Study Setting
The safety net healthcare system of San Francisco, CA,
includes residents of the City and County of San Francisco
who receive healthcare through an alliance between the
San Francisco Department of Public Health’s Community-
Oriented Primary Care, San Francisco General Hospital
and Trauma Center (SFGH), the University of California
San Francisco (UCSF), and the San Francisco Community
Clinic Consortium of independent primary care health
centers. The healthcare system serves more than 150,000
residents, including nearly 20% of San Francisco’s popu-
lation [14, 15, 18]. Socioeconomically, the population
served by the safety net healthcare system includes the
poor and indigent (many of whom receive Medicaid cov-
erage), the Medicare-insured elderly, and working indi-
viduals and families with incomes of up to 500% of the
federal poverty threshold enrolled in San Francisco’s
universal access to healthcare program (Healthy San
Francisco) [14]. The Healthy San Francisco program
ensures equal access to primary and specialty healthcare
services by providing affordable or free medical coverage
to residents who are unable to afford commercial medical
insurance but who do not qualify for Medicare (approxi-
mately 23% of patients in the healthcare system) or Med-
icaid (approximately 45% of patients in the healthcare
system) [15]. Specialty services are provided by UCSF
faculty and trainees located centrally at SFGH, including
the gastroenterology clinic, which provides gastroenterol-
ogy and hepatology services for the entire healthcare sys-
tem [19]. Patients in the healthcare system are ethnically
diverse, including 20% African Americans, 25% whites,
30% Hispanics, and 20% Asians [15]. A fully integrated
electronic medical record is used to document and coor-
dinate patient care. Patient referrals to specialty clinics are
managed through a novel electronic referral system [20].
Study Design
We performed a retrospective review of adult patients with
IBD seen in the gastroenterology clinic from November
1996 through September 2009. Records for all patients
seen in the gastroenterology clinic were electronically
queried for International Classification of Diseases, 9th
Revision (ICD9) codes 555.xx (CD), 556.xx (UC), and
558.xx (other and unspecified noninfectious gastroenteritis
and colitis), which were coded by providers at the time of
gastroenterology clinic appointments. All subcodes for
each primary code were included. Identified charts were
reviewed in detail by an investigator (JLS), including clinic
notes, hospitalization records, endoscopic evaluations,
surgical reports, laboratory testing, microbiological testing,
radiologic studies, and pathology results. IBD diagnoses
were confirmed using criteria discussed below. Data for
patients with IBD were abstracted and assimilated into a
statistical database.
Diagnosis of IBD
IBD diagnoses were confirmed using standard clinical
criteria. Subjects lacking endoscopic, pathologic, and/or
3480 Dig Dis Sci (2010) 55:3479–3487
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radiologic testing to confirm IBD diagnoses locally at
SFGH were included in the study only when historical data
were strongly consistent with IBD. We required that such
patients: (1) presented to the clinic reporting an established
history of IBD, (2) were able to provide details regarding
their disease, and (3) reported regular use of IBD medi-
cations. Patients with questionable IBD diagnosis were
excluded. Based on the consensus statement of the Mon-
treal Working Party, we designate IBD without a clear
phenotype of CD or UC as inflammatory bowel disease,
type unclassified (IBDU) [21].
Disease Extent, Location, and Behavior
We used the Montreal classification to categorize disease
among patients with CD and UC (Table 1) [21]. Subjects
lacking adequate objective data to determine the Montreal
classification were excluded from relevant data analysis.
Medication Use
Details of the subject medication use were obtained
through the careful review of clinic records. Data were
obtained regarding current and lifetime medication use. To
reduce the number of statistical comparisons in our anal-
ysis, we chose to report lifetime medication use, because
lifetime use reflects longer term utilization patterns com-
pared with current use, which provides only a snapshot in
time.
Surgical History
Reports for operative procedures performed at SFGH were
abstracted. Information regarding operative procedures
performed at other facilities was obtained from clinic
notes.
Designation of Race
As per the accepted standard [22], race was self-reported at
the time of registration at SFGH. Although the designation
of Hispanic background is considered as an ethnic identi-
fication rather than a race designation, our medical record
includes it as a race, and Hispanic patients do not identify
additional race designations (i.e., white race and Hispanic
ethnicity). We, therefore, included Hispanic identification
as a race category in our analyses.
Smoking Status
Patients were considered to be active smokers when current
cigarette use was confirmed at the most recent documen-
tation of smoking history. Patients were considered to be
prior smokers if they reported previous cigarette use, but
denied current smoking at the most recent documentation
of smoking history. Patients were considered to be non-
smokers if they denied any history of cigarette use.
Statistical Analysis
Race was the independent variable in our study, and we
sought to compare multiple dependent variables across race
groups. To reduce the number of statistical comparisons
and risk of type I error, we performed a single initial sta-
tistical test for each dependent variable to broadly evaluate
for any significant variation amongst the four race groups.
For continuous variables, we used analysis of variance
(ANOVA). For categorical variables, contingency tables
were constructed including all four race groups; Pearson’s
v2 or Fisher’s exact test evaluated for statistically signifi-
cant interracial differences. When these initial tests pro-
duced a P-value suggestive of interracial differences,
individual two-tailed t-tests (for continuous variables) or v2
or Fisher’s exact test (for categorical variables) were used
to identify specific interracial differences. The standard for
statistical significance was P B 0.05 for all analyses.
Table 1 Montreal classification scheme
Crohn’s disease
Age
A1 Diagnosis age 16 years or younger
A2 Diagnosis between age 17 and 40 years
A3 Diagnosis after age 40 years
Location
L1 Disease isolated to the ileum
L2 Disease isolated to the colon
L3 Disease of both the ileum and the colon
L4 Disease isolated to the upper gastrointestinal tract
(jejunum or proximal); can be added as a modifier
for patients with coexisting ileal and/or colonic
disease
Behavior
B1 Inflammatory; not stricturing or penetrating
B2 Stricturing, not penetrating
B3 Penetrating disease, with or without stricturing,
excludes perianal penetrating disease
Perianal
modifier
Added as a modifier for patients with perianal disease
Ulcerative colitis
Extent
E1 Disease limited to the rectum
E2 Disease proximal to the rectum but distal to the
splenic flexure
E3 Disease proximal to the splenic flexure
Based on Satsangi et al. [21]
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All analyses were performed using Stata, versions 10
and 11 (StataCorp, College Station, TX).
Ethical Considerations
This study was approved by the UCSF Committee on
Human Research and the General Clinical Research Center
at SFGH.
Results
Demographics
The study group included 228 ethnically diverse subjects,
including 105 (46.1%) whites, 34 (14.9%) blacks, 35
(15.4%) Hispanics, and 51 (22.4%) Asians. Three patients
reported other races. Compared with the overall healthcare
system, there were proportionately more white patients
(46.1 vs. 25%) and fewer Hispanic patients (15.4 vs. 30%)
in our study. The proportions of blacks and Asians in our
study were similar to the overall healthcare system [15].
The proportions of subjects from each race group were
similar to the overall San Francisco population [18] (see
Table 2).
Disease Characteristics
Objective data were available to confirm diagnoses in 187
(83%) of the subjects. The remaining 41 subjects (17%) did
not undergo further testing to confirm diagnoses within our
healthcare system. The proportion of subjects not under-
going further testing to confirm diagnosis was similar
among whites (n = 23, 21.9%), blacks (n = 6, 17.7%),
and Asians (n = 9, 17.7%); no Hispanics lacked objective
confirmatory data.
Broad interracial differences were seen among the age at
diagnosis (P \ 0.001), disease duration (P = 0.003),
family history of IBD (P = 0.01), and smoking (P \
0.001). Analysis comparing individual race pairs revealed
that Asians were diagnosed with IBD at older ages
(41.0 years) than whites (30.5 years, P \ 0.001) and
blacks (31.7 years, P = 0.005). Hispanics were diagnosed
at older ages (37.1 years) than whites (P = 0.01). Asians
and Hispanics had shorter disease durations (5.4 and
5.2 years, respectively) than whites or blacks (8.6 and
12.1 years, respectively; P B 0.05 for each comparison).
A higher proportion of whites (25.7%) had a family history
of IBD than blacks (8.8%, P = 0.04) or Asians (5.9%,
P = 0.003). Blacks (52.9%) were more likely to be current
smokers than whites (23.8%, P = 0.004), Hispanics (5.7%,
P \ 0.001), or Asians (4.8%, P \ 0.001) (see Table 2).
Table 2 Demographics and disease characteristics by race
Total population
(n = 228)a
White
(n = 105)
Black
(n = 34)
Hispanic
(n = 35)
Asian
(n = 51)
P-value
Percentage of study population – 46.1 14.9 15.4 22.4 –
Proportion of each race in the overall
healthcare system, 2007b
– 25 20 30 20 –
Proportion of each race in the overall
San Francisco population, 2008c
– 45.6 6.8 14.1 31.3 –
Female, no. (%)d 94 (41.2) 42 (40.0) 12 (35.3) 16 (45.7) 23 (45.1) 0.76
Current smoker, no. (%)d 48 (21.1) 25 (23.8) 18 (52.9) 2 (5.7) 3 (4.8) \0.001
Mean age at diagnosis, years (SD)e 34.0 (14.1) 30.5 (11.8) 31.7 (14.3) 37.1 (16.0) 41.0 (14.6) \0.001
Disease duration, years (SD)e 7.9 (9.0) 8.6 (9.4) 12.1 (13.0) 5.2 (5.5) 5.4 (5.4) 0.003
Family history of IBD, no. (%)d 37 (16.2) 27 (25.7) 3 (8.8) 4 (11.4) 3 (5.9) 0.01
Diagnosis, no. (%)d, f 0.11
Crohn’s disease 77 (33.4) 37 (35.2) 17 (50.0) 10 (28.6) 13 (25.5)
Ulcerative colitis 150 (65.8) 68 (64.8) 16 (47.1) 25 (71.4) 38 (74.5)
Inflammatory bowel disease, type unclassified 1 (0.4) 0 (0.0) 1 (2.9) 0 (0.0) 0 (0.0)
a Includes three patients with ‘‘other’’ race
b Data from [15]
c Data from [18]
d P-value calculated using contingency tables and Pearson’s v2 or Fisher’s exact test, as appropriate
e P-value calculated using analysis of variance (ANOVA)
f Comparing patients with Crohn’s disease (CD) and ulcerative colitis (UC); excludes patients with inflammatory bowel disease type unclassified
(IBDU)
3482 Dig Dis Sci (2010) 55:3479–3487
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IBD Subtype
The proportion of blacks with CD (n = 17, 50%) appeared
to be higher than other race groups (whites, n = 37, 35.2%;
Hispanics, n = 10, 28.6%; Asians, n = 13, 25.5%), despite
a P-value of 0.11 in the contingency table analysis. Given
this observation, we compared the proportions of blacks
with CD to the other three race groups individually. In this
analysis, blacks had significantly higher proportions of
CD than Asians (P = 0.015). Comparisons with whites
(P = 0.095) and Hispanics (P = 0.053) were not statisti-
cally significant (see Fig. 1).
Montreal Classification
For patients with CD, several interesting findings were
observed, including relatively high proportions of L2 dis-
ease in Asians (n = 7, 53.9%) and B1 disease in Hispanics
(n = 8, 80%), and a lack of L1 disease in Hispanics or
Asians. However, the analysis of contingency tables did not
reveal statistically significant race-based differences in the
Montreal classification of CD.
For patients with UC, the proportions of Hispanic and
Asian patients with E3 disease (68.0 and 62.5%, respec-
tively) appeared to be greater than whites or blacks (56.1
and 50.5%, respectively), but statistically significant
interracial differences were not identified (P = 0.14) (see
Table 3).
Medication Use
Broad interracial differences were identified among lifetime
immunomodulator use (P = 0.021). Use was significantly
lower among Hispanics (n = 3, 8.6%) compared with
whites (n = 26, 34.3%, P = 0.003) and blacks (n = 9,
26.5%, P = 0.05). Contingency table analysis also
suggested probable interracial differences in lifetime
5-aminosalicylate (5-ASA) use (P = 0.056) and lifetime
steroid use (P = 0.058), so we performed individual
interracial comparisons. 5-ASA use was less common
among Hispanics (n = 22, 77.1%) and blacks (n = 27,
79.4%) compared with whites (n = 97, 92.4%, P \ 0.05
for each comparison). Additionally, steroid use was less
common among Hispanics (n = 12, 34.3%) compared with
whites (n = 63, 60.0%, P = 0.008) and blacks (n = 20,
58.8%, P = 0.041). Medication was otherwise similar
among races (see Table 4).
Surgery
Although surgery for CD appeared to be more common in
blacks, no significant interracial differences were identified
(P = 0.35). Proportions of UC patients undergoing surgery
were similar across races (P = 0.997) (see Table 4).
Discussion
Among IBD patients receiving gastroenterological care in
our ethnically diverse healthcare system, we identified
several significant interracial differences in historical IBD
factors, most notably age at diagnosis, duration of disease,
and family history of IBD. Contrary to our hypothesis, IBD
subtype and Montreal classification were largely similar
among race groups. Furthermore, only minimal differences
in the medical and surgical management of IBD were
Fig. 1 Inflammatory bowel
disease (IBD) subtype by race.
*P = 0.053 compared with
blacks, **P = 0.015 compared
with blacks
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identified, and prominent differences in disease severity
and management comparing whites to minorities were not
appreciated.
The combination of older age at diagnosis and shorter
disease duration among Asians and Hispanics compared
with whites and blacks is a novel finding compared with
Table 3 Montreal classification by race
Total populationa White Black Hispanic Asian P-valueb
Crohn’s disease (n = 77)c
Montreal A class, no. (%) 0.12
A1 9 (11.7) 6 (16.2) 3 (17.7) 0 (0) 0 (0)
A2 42 (54.6) 22 (59.5) 10 (58.8) 5 (50.0) 5 (38.5)
A3 26 (33.8) 9 (24.3) 4 (23.5) 5 (50.0) 8 (61.5)
Montreal L class, no. (%) 0.30
L1 8 (10.4) 4 (10.8) 4 (23.5) 0 (0.0) 0 (0.0)
L2 23 (29.9) 9 (24.3) 5 (29.4) 2 (20.0) 7 (53.9)
L3 43 (55.8) 22 (59.5) 7 (41.2) 8 (80.0) 6 (46.2)
L4 modifier 11 (14.9) 4 (11.4) 4 (25) 0 (0.0) 3 (23.1)
Montreal B class, no. (%) 0.08
B1 53 (68.8) 23 (62.2) 12 (70.6) 8 (80.0) 10 (76.9)
B2 11 (14.3) 6 (16.2) 5 (29.4) 0 (0.0) 0 (0.0)
B3 13 (16.9) 8 (21.6) 0 (0.0) 2 (20.0) 3 (23.1)
Perianal modifier 15 (19.5) 7 (18.9) 5 (29.4) 2 (20.0) 1 (7.7)
Ulcerative colitis (n = 137)d
Montreal E class, no. (%) 0.14
E1 23 (16.8) 9 (13.6) 3 (21.4) 4 (16.0) 7 (21.9)
E2 33 (24.1) 20 (30.3) 4 (28.6) 4 (16.0) 5 (15.6)
E3 81 (59.1) 37 (56.1) 7 (50.0) 17 (68.0) 20 (62.5)
a Includes three patients with ‘‘other’’ race
b P-values calculated using contingency tables and Pearson’s v2 or Fisher’s exact test, as appropriate
c Montreal L and B classes exclude the three patients with undocumented Montreal classification (n = 74 for these classes); A class was known
for all subjects (n = 77)
d Excludes 13 patients with undocumented disease extent
Table 4 Medication use and surgical history by race
Total population
(n = 228)a
White
(n = 105)
Black
(n = 34)
Hispanic
(n = 35)
Asian
(n = 51)
P-valueb
Lifetime medication use
5-aminosalicylates, no. (%) 196 (87.1) 97 (92.4) 27 (79.4) 27 (77.1) 45 (88.2) 0.056
Immunomodulators, no. (%) 59 (26.2) 26 (34.3) 9 (26.5) 3 (8.6) 11 (21.6) 0.021
Steroids (oral or intravenous), no. (%) 121 (53.8) 63 (60.0) 20 (58.8) 12 (34.3) 26 (51.0) 0.058
Topical therapy, no. (%) 100 (44.4) 48 (45.7) 14 (41.2) 13 (37.1) 25 (49.0) 0.71
Tumor necrosis factor inhibitors,
no. (%)
23 (10.2) 12 (11.4) 4 (11.8) 3 (8.6) 4 (7.8) 0.88
Surgical history
Any surgery for Crohn’s disease,
no. (%)
32 (41.6) 15 (40.5) 10 (58.8) 3 (30.0) 4 (30.8) 0.35
Any surgery for ulcerative colitis,
no. (%)
19 (12.7) 8 (11.8) 2 (12.5) 3 (12.0) 5 (13.2) 0.997
a Includes three patients with ‘‘other’’ race
b P-values calculated using contingency tables and Pearson’s v2 or Fisher’s exact test, as appropriate
3484 Dig Dis Sci (2010) 55:3479–3487
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the two existing studies comparing IBD among three or
more race groups [12, 13]. In 2005, Basu et al. reported a
cross-sectional analysis of 148 ethnically diverse IBD
patients drawn from a single university-based gastroenter-
ology clinic in Houston, TX [12]. Age at diagnosis and
disease duration did not vary by race. The sample size
was relatively small, limiting interrace comparisons. The
recruitment of subjects from a single university-based
clinic could confer selection bias. In 2006, Nguyen and
colleagues published a cross-sectional analysis of 1,126
ethnically diverse IBD patients drawn from several centers
[13]. Age at diagnosis did not vary by race, and disease
duration was not reported. Although the study was large,
different race groups were recruited almost exclusively
from separate sites. This could not be controlled for in the
data analysis, and site-specific factors may have con-
founded the results.
Our findings lend support to the hypothesis that envi-
ronmental factors contribute to IBD pathogenesis and
course, and that changes in environmental exposures may
increase IBD risk. Specifically, though we lack data on the
immigration status of our subjects, it is likely that propor-
tionately more Hispanic and Asian subjects in our study
were first-generation immigrants compared with blacks or
whites. Previous studies document increased risk of IBD
when persons move from areas of low IBD prevalence to
areas of higher prevalence [23]. This phenomenon may
affect our patient population, which could explain the later
age at diagnosis and shorter disease duration among
Hispanics and Asians. Our study population may differ in
this regard compared with the subjects in the Basu and
Nguyen studies, which may account for our unique findings.
This hypothesis is further supported by the lower family
history of IBD in Asians compared with whites (and a
similar pattern comparing Hispanics with whites, despite
the lack of statistical significance, P = 0.078). It is
important that physicians caring for recent immigrants from
Asian and Latin American nations be aware of this likely
increased risk for IBD, particularly when patients present
with nonspecific gastrointestinal complaints of unclear eti-
ology, such as chronic diarrhea, recurrent abdominal pain,
or rectal bleeding. In such patients, delayed diagnosis
resulting in delayed onset of therapy could result in worse
outcomes [24].
Contrary to our hypothesis, only modest interracial
differences were seen in the IBD subtype. The most notable
finding was a higher proportion of CD in blacks compared
with Asians and similar-appearing differences compared
with Hispanics and whites that were not statistically sig-
nificant (P = 0.053 and 0.095, respectively). Similar dif-
ferences between blacks and other race groups were not
seen in the Basu or Nguyen studies [12, 13]. Interracial
differences in environmental exposures and/or genetics
may account for these findings. Specifically, high rates of
smoking among blacks in our study may contribute to the
differences, a hypothesis supported by similar rates of both
smoking and CD in blacks compared with whites in the
Basu and Nguyen studies [12, 13]. Genetic factors con-
tributing to IBD are not well-characterized among non-
white patients. Blacks, Hispanics, and Asians with CD are
less likely than whites to have common NOD2 mutations
[25–27]. Additionally, multiple studies of IBD genetics
have been recently published among Asian cohorts
[28–30]. The genetic study of IBD among nonwhite
patients remains limited and is an important area for future
research.
Also contrary to our hypothesis, we identified no sig-
nificant interracial differences in the Montreal classifica-
tion. This may be due, in part, to our study design, in which
patients were drawn from the same center, which reduces
center-specific influences that may affect interracial com-
parisons in other studies. For CD patients, the lack of dif-
ferences may also reflect, in part, limitations of a modest
sample size. For example, no Hispanic or Asian patients had
isolated terminal ileal CD, and no blacks had penetrating
CD, yet the P-values did not indicate statistical significance.
It is possible that, with a larger sample, significant differ-
ences would be seen. For UC patients, however, proportions
of patients with proctitis, left-sided colitis, and extensive
colitis were numerically similar among races, suggesting a
true lack of interracial difference.
Although minority patients with IBD received different
medical and surgical therapy than whites in other studies
[12, 13, 31], we identified relatively few interracial dif-
ferences. Notably, Hispanics received 5-ASA compounds,
immunomodulators, and steroids less often than whites.
The reasons for this are not clear. Hispanics were not more
likely to undergo IBD-related surgery, which might be seen
if they had disease of similar severity but were under-
treated. It is possible that Hispanics in our study had milder
disease, a hypothesis that can only be addressed in a pro-
spective study. The relative lack of interracial differences
in the management of IBD may reflect the minimization of
race-based healthcare disparities in our healthcare system
in which all patients had equal access to healthcare.
Our study population is of lower socioeconomic status
than the general United States population, which raises the
question of whether socioeconomic status was associated
with IBD phenotype or therapy in our patients. Comparing
patients of lower and higher monthly income in our pop-
ulation, we identified no significant differences in the IBD
phenotype or medical or surgical therapy (data not shown).
Comparisons with a higher income population would be an
interesting direction for future research.
Our study has several specific strengths. The inclusion
of IBD patients from an entire healthcare system may
Dig Dis Sci (2010) 55:3479–3487 3485
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reduce selection bias and improve generalizability.
Although our patient population is of significantly lower
socioeconomic status than the general United States pop-
ulation (mean annual income in our population was
$8,256), the relative proportions of different race groups
among our IBD patients were similar to the overall
San Francisco population (Table 2). Furthermore, the race-
specific proportions of CD versus UC in our study popu-
lation are similar to those from a large study of the
Northern California Kaiser Permanente population (a
managed care population in geographic proximity to our
center with 3.2 million members; 8,787 IBD patients were
included in the study) [32]. These similarities to large
populations support the generalizability of our results. All
of the subjects in our study had equal healthcare access
within the system, receiving care from the same gastro-
enterology faculty. This reduces potential confounding
from site-specific factors and, importantly, disparities in
healthcare access.
We identified a relatively modest number of patients with
IBD over a 13-year period. This may, in part, reflect the
racial breakdown of our overall healthcare system, in which
whites are underrepresented and blacks and Hispanics are
overrepresented, compared with the overall San Francisco
population (Table 2). Because we included only IBD
patients seen in the gastroenterology clinic, patients with
mild IBD manageable by primary care physicians might not
have been referred to the gastroenterology clinic and would,
therefore, not be included in our study. Given our modest
sample size with many potential dependent variables, we
designed our statistical analysis to reduce the risk of com-
mitting type I error, which is more counterproductive than
type II error. This methodology may not identify all differ-
ences that are truly present in our study population. Each of
our race groups includes, to varying degrees, an ethnically
diverse group of subjects. We do not have detailed infor-
mation on ethnicity (i.e., Chinese versus Japanese versus
Indian for Asians, or Mexican versus Salvadoran for His-
panics), but this is not likely to affect our results in a pre-
dictable manner. We relied on ICD9 codes to identify
patients with IBD, and it is possible that some IBD patients
were not identified due to miscoding. As most patients were
seen multiple times in the clinic, and ICD9 codes were
entered at each visit, we believe that our study captures the
vast majority of IBD patients in our healthcare system, and
the utility of using administrative data to identify IBD
patients is supported by other authors [33]. Finally, reliance
on chart review may result in incomplete data for some
patients, but race itself is unlikely to affect data complete-
ness, and this limitation is unlikely to bias our findings.
In summary, we present evidence supporting later age at
diagnosis, shorter disease duration, and less frequent family
history of IBD among Hispanic and Asian IBD patients.
Despite these differences, the IBD subtype, Montreal dis-
ease classification, and medical and surgical therapy were
largely similar among races.
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